Home › NDC Lookup › Ingredients › Multiple Vitamins Injection › 54643-5649-01
Infuvite Adult multiple vitamins injection Kit — NDC 54643-5649-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Infuvite Adult multiple vitamins injection Kit — NDC 54643-5649-1 (Billing 54643-5649-01)

by Sandoz Inc · 10 VIAL in 1 CARTON / 5 mL in 1 VIAL

This is a package of Infuvite Adult multiple vitamins injection Kit from Sandoz Inc, marketed since May 2005 and currently FDA-listed; retail pharmacies pay about $0.9037 per mL (NADAC). It is this product's only package size.

NDC 54643-5649-01
🏷️ FDA NDC (as labeled) 54643-5649-1 billing pads the package segment with a zero
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🚨
Active recall for this product.
Class II · Apr 25, 2025 — Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product. (Mckesson Medical-Surgical Inc. Corporate Office) · FDA recall D-0401-2025
Lots / codes: Lot #: AA2279, Exp 8/31/26; AA2383, Exp 9/30/26 · reported May 7, 2025
Check your lot/expiration against the official notice — look up the recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 54643-5649-1
Product NDC 54643-5649
11-digit billing NDC 54643564901
NCPDP billing unit ML — per mL (volume)
RxCUI 1304559, 1304564
Application # NDA021163
SPL Set ID 14c7bfc5-07e8-400f-b8ff-5e4794dd2805
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2005-05-18
Dosage form KIT
TE code (Orange Book) AP · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 78200000002020
GPI class Infuvite Adult
GCN Seq No 068502
GCN 31299
HICL code 038448
Ingredient (HICL) Multivit Infusn,Adult 4,Vit K
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C6
Therapeutic class — intermediate (HIC2) Vitamins
HIC3 code C6Z
Therapeutic class — specific (HIC3) Multivitamin Preparations
AHFS code 88:24.00.00
AHFS class Vitamin K Activity
FDB label name INFUVITE ADULT VIAL
FDB brand name Infuvite Adult
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 068502
  • GCN: 31299
  • GPI-14 (Medi-Span): 78200000002020
  • HICL (First Databank): 038448
  • AHFS class code: 88:24.00.00
  • RxCUI (RxNorm): 1304559
Why two NDCs? The FDA registers this code as 54643-5649-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 54643-5649-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Vitamin B1, plain class.

Drug family (ATC) Vitamin B1, plain
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name INFUVITE ADULT VIAL Ingredient Multivit Infusn,Adult 4,Vit K

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.904 $45.19 / 50 ml
Medicaid paysCMS SDUD · 12 mo $2.20 $109.99 / 50 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2025 Feb 2026 Apr 2026 Jul 2026 $0.990 $0.904
▼ Down 8% over the last 8 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
54643-5649-01 You're viewing this Main listing 10 VIAL in 1 CARTON / 5 mL in 1 VIAL 2005-05-18 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Infuvite Adultthis 54643-5649-01 Sandoz 10 vials $0.904 AP Availability likely —
Infuvite Adult 54643-5650-02 Sandoz 2 vials — AP FDA listed —
Infuvite Pediatric 54643-5646-00 Sandoz 2 vials — AP FDA listed —
Infuvite Pediatric 54643-5647-00 Sandoz 1 kit — AP FDA listed —
About this product: this is the brand-name version. Some generic versions are approved by the FDA, but we could not confirm current pharmacy availability from our pricing/market data.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2005
On the market since
May 2005
📍
2026
Currently FDA-listed
21 years listed
🔒
·
Generic approved (availability unconfirmed)
see note
🔒Generic approved by FDA, but pharmacy availability is not confirmed

The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

A current SPL was checked, but it does not contain a structured or narrative inactive-ingredient list for this product. This does not mean the product has no inactive ingredients.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerSandoz Inc
Application holderSANDOZ CANADA INC
FDA applicationNDA021163 (NDA)
Labeler code54643
First marketedMay 2005
Product typeHuman Prescription Drug
Portfolio391 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients 🧪 Nonclinical Toxicology 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 73 words ▾

1 INDICATIONS AND USAGE INFUVITE ADULT is a combination of vitamins indicated for the prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition. The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. INFUVITE ADULT is a combination of vitamins indicated for prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition ( 1 )

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION • INFUVITE ADULT is a combination product that contains the following vitamins: ascorbic acid, vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, dexpanthenol, vitamin E, vitamin K 1 , folic acid, biotin, and vitamin B 12 ( 2.1 ) • INFUVITE ADULT is for administration by intravenous infusion after dilution ( 2.1 ) • Recommended daily dosage is 10 mL ( 2.1 ) • INFUVITE ADULT is supplied as a single dose and as a pharmacy bulk package. o Single Dose : Add one daily dose of 10 mL (5 mL from Vial 1 and 5 mL from Vial 2) to not less than 500 mL, and preferably 1000 mL, of intravenous dextrose, saline or similar infusion solutions.

( 2.2 ) o Pharmacy Bulk Package : Add the contents of Vial 1 to the contents of Vial 2. This provides ten 10 mL daily doses. Take 10 mL from Vial 2 and add to not less than 500 mL, and preferably 1000 mL, of intravenous dextrose, saline or similar infusion solutions.

( 2.2 ) • After dilution in an intravenous infusion, refrigerate resulting solution unless used immediately. Use solution within 24 hours after dilution ( 2.2 ) • Monitor blood vitamin concentrations ( 2.3 ) • See Full Prescribing Information for drug incompatibilities ( 2.4 )

2.1Important Dosage Instructions INFUVITE ADULT is a combination product that contains the following vitamins: ascorbic acid, vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, dexpanthenol, vitamin E, vitamin K 1 , folic acid, biotin, and vitamin B 12 . INFUVITE ADULT is supplied as a single dose or as a pharmacy bulk package for intravenous use intended for administration by intravenous infusion after dilution. INFUVITE ADULT Single Dose: • Provides one daily dose of 10 mL (5 mL of Vial 1 plus 5 mL of Vial 2) which must be diluted prior to intravenous administration [see Dosage and Administration ( 2.2 )] .

INFUVITE ADULT Pharmacy Bulk Package: • Provides ten 10 mL daily doses when the content of vial 1 is transferred into the content of vial 2. One 10 mL dose is then added directly to intravenous fluid. Pharmacy bulk package of INFUVITE ADULT is intended for dispensing of single doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion [see Dosage and Administration ( 2.2 )].

Patients with multiple vitamin deficiencies or with increased vitamin requirements may need multiple daily dosages as indicated. Some patients do not maintain adequate levels of certain vitamins when this formulation in recommended amounts is the only source of vitamins.

2.2Preparation and Administration Instructions Do not administer INFUVITE ADULT as a direct, undiluted intravenous injection as it may cause dizziness, faintness, and possible tissue irritation . INFUVITE ADULT Single Dose : • Use only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). • Add 5 mL of Vial 1 and 5 mL of Vial 2 to at least 500 mL to 1000 mL, of intravenous dextrose or saline solutions. • Discard unused portion. • Visually inspect for particulate matter and discoloration prior to administration. • After INFUVITE ADULT is diluted in an intravenous infusion, refrigerate the resulting solution unless it is to be used immediately, and use the solution within 24 hours after dilution. • Minimize exposure to light because some of the vitamins in INFUVITE ADULT, particularly A, D and riboflavin, are light sensitive.

INFUVITE ADULT Pharmacy Bulk Package : • Use only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). • Transfer the contents of Vial 1 into the contents of Vial 2 to provide ten 10 mL single doses. • Each bulk vial closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. • Once the closure system has been penetrated, complete dispensing from the pharmacy bulk vial should be completed within 4 hours.… [Excerpted — this section continues on DailyMed.]

💊 Dosage Forms and Strengths 217 words ▾

3 DOSAGE FORMS AND STRENGTHS INFUVITE ADULT Single Dose: is an injection for intravenous administration consisting of two vials labeled Vial 1 (5 mL) and Vial 2 (5 mL). For the vitamin strengths [see Description ( 11 )]. INFUVITE ADULT Pharmacy Bulk Package : is an injection for intravenous administration consisting of two vials labeled Vial 1 (50 mL) and Vial 2 (50 mL Fill in 100 mL Vial).

The mixed solution (100 mL) will provide ten 10 mL single doses. For the vitamin strengths [see Description ( 11 )]. Vial 1 (Single Dose and Pharmacy Bulk Package) is supplied as clear, yellow to orange liquid in amber glass vial closed with a rubber stopper, clear aluminum seal and a white flip-off.

Vial 2 (Single Dose and Pharmacy Bulk Package) is supplied as clear, colorless to pale yellow liquid in amber glass vial closed with a rubber stopper, clear aluminum seal and a deep purple flip-off. • INFUVITE ADULT supplied as single dose is an injection consisting of two vials labeled Vial 1 (5 mL) and Vial 2 (5 mL) ( 3 ) • INFUVITE ADULT supplied as a pharmacy bulk package is an injection consisting of two vials labeled Vial 1 (50 mL) and Vial 2 (50 mL fill in 100 mL Vial) ( 3 )

⛔ Contraindications 48 words ▾

4 CONTRAINDICATIONS INFUVITE ADULT is contraindicated in patients who have • An existing hypervitaminosis, or • A history of hypersensitivity due to any vitamins or excipients contained in this formulation. • Hypersensitivity to any of the vitamins or excipients ( 4 ) • Existing hypervitaminosis ( 4 )

⚠️ Warnings and Cautions ~2 min read ▾

5 WARNINGS AND PRECAUTIONS • Risk of Aluminum Toxicity: For at risk patients (renal failure or those with prolonged therapy), consider periodic monitoring of aluminum levels ( 5.1 ) • Allergic Reactions: To thiamine may occur ( 5.2 ) • Hypervitaminosis A : Patients with renal failure or liver disease may be at higher risk ( 5.3 ) • Decreased Anticoagulant Effect of Warfarin: Monitor INR ( 5.4 , 7.1 ) • Interferes with Megaloblastic Anemia Diagnosis: Avoid during testing for this disorder ( 5.5 ) • Risk of Vitamin Deficiencies or Excesses: Monitor blood vitamin concentrations ( 5.6 ) • False Negative Urine Glucose Tests: Due to vitamin C ( 5.7 )

5.1Aluminum Toxicity INFUVITE ADULT contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solution, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. To prevent aluminum toxicity periodically monitor aluminum levels with prolonged parenteral administration of INFUVITE ADULT in patients with renal impairment.

5.2Allergic Reactions to Thiamine Allergic reactions such as urticaria, shortness of breath, wheezing and angioedema have been reported following intravenous administration of thiamine, which is found in INFUVITE ADULT. There have been rare reports of anaphylactoid reactions following intravenous doses of thiamine. No fatal anaphylactoid reactions associated with INFUVITE ADULT have been reported.

5.3. Hypervitaminosis A Hypervitaminosis A, manifested by nausea, vomiting, headache, dizziness, blurred vision has been reported in patients with renal failure receiving 1.5 mg/day retinol and in patients with liver disease, Therefore, supplementation of renal failure patients and patients with liver disease with vitamin A, an ingredient found in INFUVITE ADULT, should be undertaken with caution [see Use in Specific Populations ( 8.6 and 8.7 )].

5.4Decreased Anticoagulant Effect of Warfarin INFUVITE ADULT contains Vitamin K, which may decrease the anticoagulant action of warfarin. In patients who are on warfarin anticoagulant therapy receiving INFUVITE ADULT monitor blood levels of prothrombin/INR to determine if dose of warfarin needs to be adjusted.

5.5Interference with Diagnosis of Megaloblastic Anemia INFUVITE ADULT contains folic acid and cyanocobalamin which can mask serum deficiencies of folic acid and cyanocobalamin in patients with megaloblastic anemia. Avoid the use of INFUVITE ADULT in patients with suspected or diagnosed megaloblastic anemia prior to blood sampling for the detection of the folic acid and cyanocobalamin deficiencies.

5.6Potential to Develop Vitamin Deficiencies or Excesses In patients receiving parenteral multivitamins such as with INFUVITE ADULT, blood concentration should be periodically monitored to determine if deficiencies or excesses are developing. INFUVITE ADULT may not correct long-standing specific vitamin deficiencies. The administration of additional therapeutic doses of specific vitamins may be required [see Dosage and Administration ( 2.3 )].

5.7Interference with Urine Glucose Testing INFUVITE ADULT contains vitamin C which is also known as ascorbic acid. Ascorbic acid in the urine may cause false negative urine glucose results.

🤒 Adverse Reactions 137 words ▾

6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other section of the labeling. • Allergic reactions to thiamine [see Warnings and Precautions ( 5.2 )] • Hypervitaminosis A [see Warnings and Precautions ( 5.3 )] The following adverse reactions have been identified during postapproval use of INFUVITE ADULT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Dermatologic: rash, erythema, pruritis CNS: headache, dizziness, agitation, anxiety Ophthalmic: diplopia Adverse reactions have included anaphylaxis and anaphylactoid reactions including shortness of breath, wheezing and angioedema, rash, erythema, pruritis, headache, dizziness, agitation, anxiety, diplopia ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

🔄 Drug Interactions ~2 min read ▾

7 DRUG INTERACTIONS A number of interactions between vitamins and drugs have been reported. The following are examples of these types of interactions: Effect of INFUVITE ADULT on other drugs: • Antibiotics: Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid decrease activities of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin ( 7.1 ) • Bleomycin: Ascorbic acid and riboflavin may reduce the activity of bleomycin ( 7.1 ) • Levodopa: Pyridoxine may decrease blood levels of levodopa and levodopa efficacy may decrease ( 7.1 ) • Phenytoin: Folic acid may decrease phenytoin blood levels and increase risk of seizure activity ( 7.1 ) • Methotrexate: Folic acid may decrease response to methotrexate ( 7.1 ) Effects of other drugs on INFUVITE ADULT: • Hydralazine, Isoniazid: Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements ( 7.2 ). • Phenytoin: May decrease folic acid concentrations ( 7.2 ) • Chloramphenicol : In patients with pernicious anemia, the hematologic response to vitamin B12 therapy may be inhibited ( 7.2 )

7.1Drug Interactions Affecting Co-Administered Drugs Warfarin : Vitamin K, a component of INFUVITE ADULT, antagonizes the anticoagulant action of warfarin. In patients who are co-administered warfarin and INFUVITE ADULT, blood levels of prothrombin/INR should be monitored to determine if dose of warfarin needs to be adjusted [see Warnings and Precautions ( 5.4 )]. Antibiotics : Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid decrease antibiotic activities of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin.

Bleomycin : Ascorbic acid and riboflavin inactivate bleomycin in vitro , thus the activity of bleomycin may be reduced. Levodopa : Pyridoxine may increase the metabolism of levodopa (decrease blood levels of levodopa) and decrease its efficacy. Phenytoin: Folic acid may increase phenytoin metabolism and lower the serum concentration of phenytoin resulting in increased seizure activity.

Methotrexate: Folic acid may decrease a patient’s response to methotrexate therapy.

7.2Drug Interactions Affecting Vitamin Levels Hydralazine, Isoniazid: Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements. Phenytoin : Phenytoin may decrease serum folic acid concentrations. Chloramphenicol: In patients with pernicious anemia, the hematologic response to vitamin B 12 therapy may be inhibited by chloramphenicol.

👥 Use in Specific Populations ~2 min read ▾

8 USE IN SPECIFIC POPULATIONS • Pregnancy and Lactation: Pregnant and lactating patients should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirements may exceed those of nonpregnant and nonlactating patients ( 8.1 , 8.2 ) • Renal Impairment: Monitor renal function, calcium, phosphorus and vitamin A levels in patients with renal impairment ( 8.6 ) • Hepatic Impairment: Monitor vitamin A level in patients with liver disease, high alcohol consumption ( 8.7 )

8.1Pregnancy Risk Summary Administration of the approved recommended dose of INFUVITE ADULT in parental nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Pregnant patients should follow the U.S. Recommended Daily Allowances for pregnancy because their vitamin requirements may exceed those of nonpregnant patients.

Deficiency of essential vitamins may result in adverse pregnancy outcomes (see Clinical Considerations) . Animal reproduction studies have not been conducted with INFUVITE ADULT. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo-Fetal Risk Deficiency of essential vitamins has been associated with adverse pregnancy and fetal outcomes, such as maternal folic acid deficiency and an increased risk of neural tube defects.

Therefore, parenteral nutrition with multiple vitamins injection should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake.

8.2Lactation Risk Summary Multiple vitamins present in INFUVITE ADULT are also present in human milk. Administration of the approved recommended dose of INFUVITE ADULT In parental nutrition is not expected to cause harm to a breastfed infant. There is no information on the effects of INFUVITE ADULT on milk production.

Lactating patients should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirements may exceed those of nonlactating patients. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for INFUVITE ADULT and any potential adverse effects on the breastfed child from INFUVITE ADULT or from the underlying maternal condition.

8.4Pediatric Use Safety and effectiveness in children below the age of 11 years have not been established.

8.5Geriatric Use Safety and effectiveness for geriatric use have not been established.

8.6Renal Impairment INFUVITE ADULT has not been studied in patients with renal impairment. Monitor renal function, calcium, phosphorus and vitamin A levels in patients with renal impairment [see Warnings and Precautions ( 5.1 and 5.3 )].

8.7Hepatic Impairment INFUVITE ADULT has not been studied in patients with liver impairments. Monitor vitamin A level in patients with liver disease, high alcohol consumption [see Warnings and Precautions ( 5.3 )].

🤰 Pregnancy 188 words ▾

8.1Pregnancy Risk Summary Administration of the approved recommended dose of INFUVITE ADULT in parental nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Pregnant patients should follow the U.S. Recommended Daily Allowances for pregnancy because their vitamin requirements may exceed those of nonpregnant patients.

Deficiency of essential vitamins may result in adverse pregnancy outcomes (see Clinical Considerations) . Animal reproduction studies have not been conducted with INFUVITE ADULT. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo-Fetal Risk Deficiency of essential vitamins has been associated with adverse pregnancy and fetal outcomes, such as maternal folic acid deficiency and an increased risk of neural tube defects.

Therefore, parenteral nutrition with multiple vitamins injection should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake.

🧒 Pediatric Use 18 words ▾

8.4Pediatric Use Safety and effectiveness in children below the age of 11 years have not been established.

🧓 Geriatric Use 13 words ▾

8.5Geriatric Use Safety and effectiveness for geriatric use have not been established.

🆘 Overdosage 37 words ▾

10 OVERDOSAGE Signs and symptoms of acute or chronic overdosage may be those of individual INFUVITE ADULT component toxicity. In post-marketed surveillance, overdosage with INFUVITE ADULT at two times the prescribed dose did not result in toxicity.

📦 How Supplied / Storage and Handling 211 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied INFUVITE ADULT (multiple vitamins injection) is supplied as follows: Vial 1 (Single Dose and Pharmacy Bulk Package) is supplied as clear, yellow to orange liquid in amber glass vial closed with a rubber stopper, clear aluminum seal and a white flip-off. Vial 2 (Single Dose and Pharmacy Bulk Package) is supplied as clear, colorless to pale yellow liquid in amber glass vial closed with a rubber stopper, clear aluminum seal and a deep purple flip-off. INFUVITE ADULT Single Dose : Carton contains total ten single-dose vials NDC 54643-5649-1 Five of Vial 1 (5 mL) NDC 54643-5657-1 Five of Vial 2 (5 mL) NDC 54643-5659-1 one Vial 1 plus one Vial 2 to be used for a single dose [see Dosage and Administration ( 2.1 )].

INFUVITE ADULT Pharmacy Bulk Package: Carton contains total two vials NDC 54643-5650-2 One Vial 1 (50 mL) NDC 54643-5661-2 One Vial 2 (50 mL Fill in 100 mL Vial) NDC 54643-5663-2 Mix contents of Vial 1 with Vial 2 to provide 10 single doses [see Dosage and Administration ( 2.1 )]. Storage and Handling Minimize exposure of INFUVITE ADULT to light because vitamins A, D and riboflavin are light sensitive. Store under refrigeration, 2°C to 8°C (36°F to 46°F).

📋 Description ~1 min read ▾

11 DESCRIPTION INFUVITE ADULT (multiple vitamins injection) is a sterile product consisting of two vials provided as a single dose or as a pharmacy bulk package, both intended for intravenous use for administration by intravenous infusion after dilution: INFUVITE ADULT Single Dose - two 5 mL single-dose vials labeled Vial 1 and Vial 2. INFUVITE ADULT Pharmacy Bulk Package - two vials – 1 each of Vial 1 (50 mL) and Vial 2 (50 mL Fill in 100 mL Vial). The mixed solution (100 mL) will provide ten 10 mL single doses.

Each 5 mL of Vial 1 contains: Ascorbic acid (Vitamin C) 200 mg Vitamin A * (as palmitate) 3,300 IU Vitamin D 3 * (cholecalciferol) 200 IU Thiamine (Vitamin B 1 ) (as the hydrochloride) 6 mg Riboflavin (Vitamin B 2 ) (as riboflavin 5-phosphate sodium) 3.6 mg Pyridoxine HCl (Vitamin B 6 ) 6 mg Niacinamide 40 mg Dexpanthenol (as d -pantothenyl alcohol) 15 mg Vitamin E * ( dl -α-tocopheryl acetate) 10 IU Vitamin K 1 * 150 mcg *Polysorbate 80 is used to water solubilize the oil-soluble vitamins A, D, E, and K. Inactive ingredients: 1.4% polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection.

Each 5 mL of Vial 2 contains: Folic acid 600 mcg Biotin 60 mcg Vitamin B 12 (cyanocobalamin) 5 mcg Inactive ingredients: 30% propylene glycol, citric acid and/or sodium citrate for pH adjustment, and water for injection. INFUVITE ADULT makes available a combination of important oil-soluble and water-soluble vitamins in an aqueous solution, formulated for incorporation into intravenous solutions. The liposoluble vitamins A, D, E, and K have been solubilized in an aqueous medium with polysorbate 80, permitting intravenous administration of these vitamins.

Contains no more than 70 mcg/L of aluminum (combined Vials 1 and 2).

💬 Information for Patients ~1 min read ▾

17 PATIENT COUNSELING INFORMATION Instruct patients (if age appropriate) and caregivers: • To watch for signs of allergic reactions such as urticaria, shortness of breath, wheezing and angioedema since hypersensitivity reactions may occur to any of the vitamins or excipients contained in INFUVITE ADULT. • To watch for and immediately report nausea, vomiting, headache, dizziness, blurred vision, especially if patients have renal impairment, as these may be signs of hypervitaminosis A. • To report other adverse reactions such as rash, erythema, pruritus, headache, dizziness, agitation, anxiety, and diplopia. • That the patients on warfarin anticoagulant therapy will be monitored periodically with blood prothrombin/ INR levels to determine if their dose of warfarin needs to be adjusted. • About the significance of periodic monitoring of blood vitamin concentrations to determine if vitamin deficiencies or excesses are developing and the need to monitor renal function, calcium, phosphorus, aluminum and vitamin A levels in patients with renal impairment. • That INFUVITE ADULT should be avoided in patients with suspected or diagnosed megaloblastic anemia prior to blood sampling for the detection of the folic acid and cyanocobalamin deficiencies. • That vitamin C (ascorbic acid) contained in INFUVITE ADULT may cause false negative urine glucose results.

Manufactured for Sandoz Inc. , Princeton, NJ 08540 Distributed by Baxter Healthcare Corporation Deerfield, IL 60015 USA INFUVITE is a registered trademark of Sandoz Canada Inc. 5001527

🧪 Nonclinical Toxicology 21 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity, mutagenicity, and fertility studies have not been performed with INFUVITE ADULT.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 18 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity, mutagenicity, and fertility studies have not been performed with INFUVITE ADULT.

📄 Package Label / Principal Display Panel 115 words ▾

Infuvite Adult Single Dose Vials Carton NDC 54643-5649-1 Rx Only Sterile INFUVITE ® ADULT (multiple vitamins injection) Contents: Five of Vial 1 (5 mL) and Five of Vial 2 (5 mL). One vial of each to be used for a single dose. Discard Unused Portion. For Intravenous Infusion Must be diluted before use. Baxter adult-single-dose-carton

Infuvite Adult Pharmacy Bulk Vials Carton NDC 54643-5650-2 Rx Only Sterile INFUVITE® ADULT (multiple vitamins injection) PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION Contents: One Vial 1 (50 mL) and One Vial 2 (50 mL fill in 100 mL Vial). Both vials combined produce 10 single doses. Discard Unused Portion For Intravenous Infusion Must be diluted before use. Baxter infuvite-adult-pbp-carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
31.5K
Units reimbursed last 4 qtrs
1.6M
Gross reimbursed last 4 qtrs
$3.61M
Avg / prescription
$114.62
Avg / unit
$2.1997
Latest quarter Q1 2026
7.3KRx
Medicaid pays / mL
$2.1997
gross reimbursed
vs
NADAC / mL
$0.9037
acquisition cost
=
Spread
+$1.2960
+143% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
68% FFS 32% MCO
Fee-for-service · 21,379 Rx Managed care · 10,082 Rx
State Medicaid map
Alaska: 10,223 units · 1,395 per 100k residents AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: 3,064 units · 271 per 100k residents MT North Dakota: 437 units · 55.8 per 100k residents ND Minnesota: 1,409 units · 24.6 per 100k residents MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 1,160 units · 5.9 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 2,540 units · 60.0 per 100k residents OR Nevada: 1,420 units · 44.5 per 100k residents NV Wyoming: no data reported WY South Dakota: 205 units · 22.3 per 100k residents SD Iowa: 22 units · 0.7 per 100k residents IA Illinois: 156,300 units · 1,246 per 100k residents IL Indiana: 2,694 units · 39.3 per 100k residents IN Ohio: 139,759 units · 1,186 per 100k residents OH Pennsylvania: 8,587 units · 66.3 per 100k residents PA New Jersey: 19,357 units · 208 per 100k residents NJ Massachusetts: 129 units · 1.8 per 100k residents MA California: 830,838 units · 2,132 per 100k residents CA Utah: 5,854 units · 171 per 100k residents UT Colorado: 148,930 units · 2,534 per 100k residents CO Nebraska: no data reported NE Missouri: 9,635 units · 156 per 100k residents MO Kentucky: 1,541 units · 34.0 per 100k residents KY West Virginia: no data reported WV Virginia: 200 units · 2.3 per 100k residents VA Maryland: 24,593 units · 398 per 100k residents MD Connecticut: 82,720 units · 2,287 per 100k residents CT Rhode Island: no data reported RI Arizona: 240 units · 3.2 per 100k residents AZ New Mexico: 245 units · 11.6 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 274 units · 3.8 per 100k residents TN North Carolina: no data reported NC South Carolina: 18,440 units · 343 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 16,328 units · 357 per 100k residents LA Mississippi: 666 units · 22.7 per 100k residents MS Alabama: 45,090 units · 883 per 100k residents AL Georgia: 9,872 units · 89.5 per 100k residents GA D.C.: 49 units · 7.2 per 100k residents DC Hawaii: 190 units · 13.2 per 100k residents HI Texas: 11 units · 0.0 per 100k residents TX Florida: 96,280 units · 426 per 100k residents FL
Units reimbursed · per 100k residents
0.02,534
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Colorado 2,534 /100k
2 Connecticut 2,287 /100k
3 California 2,132 /100k
4 Alaska 1,395 /100k
5 Illinois 1,246 /100k
6 Ohio 1,186 /100k
7 Alabama 883 /100k
8 Florida 426 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Infuvite Adult (this brand).

Top reported reactions

Flushing32
Dyspnoea31
Chest Discomfort25
Infusion Related Reaction18
Nausea15
Dizziness13
Vomiting13

Age at onset

Adult5
Elderly1

Reporter sex

133 reports
Male · 9%
Female · 90%
Unknown · 1%

Serious outcomes

Hospitalization7
Life-threatening4
Death1
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 20 6
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product Kit / multi-component package

Kit / multi-component package

This NDC identifies a kit — a package containing more than one component. Structured data (pricing, ingredients, equivalents) is often reported per component rather than for the kit NDC itself, which can make this page look thinner than the components' own pages.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Sandoz Inc. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Sandoz Inc is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 54643-5647-00 · Sandoz 54643-5650-02 · Sandoz →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.